CL2016000030A1 - Bencil-1h-pirazolo[3,4-b]piridinas y su uso - Google Patents

Bencil-1h-pirazolo[3,4-b]piridinas y su uso

Info

Publication number
CL2016000030A1
CL2016000030A1 CL2016000030A CL2016000030A CL2016000030A1 CL 2016000030 A1 CL2016000030 A1 CL 2016000030A1 CL 2016000030 A CL2016000030 A CL 2016000030A CL 2016000030 A CL2016000030 A CL 2016000030A CL 2016000030 A1 CL2016000030 A1 CL 2016000030A1
Authority
CL
Chile
Prior art keywords
disorders
pyrazolo
pyridines
benzyl
hypertension
Prior art date
Application number
CL2016000030A
Other languages
English (en)
Inventor
Adrian Tersteegen
Alexandros Vakalopoulos
Alexey Gromov
Markus Follmann
Damian Brockschnieder
Johannes-Peter Stasch
Tobias Marquardt
Frank Wunder
Gorden Redlich
Dieter Lang
Volkhart Min-Jian Li
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2016000030A1 publication Critical patent/CL2016000030A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPUESTOS DERIVADOS DE BENCIL-1H-PIRAZOLO[3,4-B]PIRIDINAS; MEDICAMENTO; Y SU USO PARA EL Tratamiento y/o profilaxis de falla cardiaca, angina pectoris, hipertensión, hipertensiOn pulmonar, isquemias, trastornos vasculares, insuficiencia renal. trastornos tromboembolicos, trastornos fibroticos, arteriosclerosis, trastornos de demencia y disfuncio erectil
CL2016000030A 2013-07-10 2016-01-08 Bencil-1h-pirazolo[3,4-b]piridinas y su uso CL2016000030A1 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP13175889 2013-07-10
EP13175892 2013-07-10
EP13175898 2013-07-10
EP13175899 2013-07-10
EP13175890 2013-07-10
EP13175903 2013-07-10
EP13175896 2013-07-10
EP13175904 2013-07-10
EP13175895 2013-07-10
EP13175894 2013-07-10

Publications (1)

Publication Number Publication Date
CL2016000030A1 true CL2016000030A1 (es) 2016-08-19

Family

ID=51162805

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000030A CL2016000030A1 (es) 2013-07-10 2016-01-08 Bencil-1h-pirazolo[3,4-b]piridinas y su uso

Country Status (22)

Country Link
US (1) US9605008B2 (es)
EP (1) EP3019506A1 (es)
JP (1) JP2016523944A (es)
KR (1) KR20160030541A (es)
CN (1) CN105745215A (es)
AP (1) AP2016008970A0 (es)
AU (1) AU2014289312A1 (es)
CA (1) CA2917682A1 (es)
CL (1) CL2016000030A1 (es)
CU (1) CU20160004A7 (es)
DO (1) DOP2016000006A (es)
EA (1) EA201600096A1 (es)
GT (1) GT201600002A (es)
IL (1) IL243525A0 (es)
MX (1) MX2016000258A (es)
PE (1) PE20160201A1 (es)
PH (1) PH12016500065A1 (es)
SG (1) SG11201600038UA (es)
TN (1) TN2016000006A1 (es)
TW (1) TW201542569A (es)
UY (1) UY35652A (es)
WO (1) WO2015004105A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
TN2017000465A1 (en) 2015-05-06 2019-04-12 Bayer Pharma AG The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
LT3325013T (lt) 2015-07-23 2020-11-10 Bayer Pharma Aktiengesellschaft Tirpios guanilatciklazės (sgc) stimuliatoriai/aktyvatoriai derinyje su nep inhibitoriumi ir (arba) angiotenzino aii antagonistu ir jų naudojimas
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017121692A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte sulfamide und ihre verwendung
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
ES2985316T3 (es) 2016-10-11 2024-11-05 Bayer Pharma AG Combinación que contiene el estimulador sGC vericuguat y el antagonista de los receptores de corticoides minerales finerenona
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
KR102615821B1 (ko) 2017-04-11 2023-12-21 선샤인 레이크 파르마 컴퍼니 리미티드 불소-치환된 인다졸 화합물 및 이의 용도
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se Substituted cyclopropyl derivatives
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
EP4188931A2 (en) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
CN120754115A (zh) * 2025-05-23 2025-10-10 远大医药（中国）有限公司 一种含依普利酮组合物及其药物制剂、制备方法和用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8601208A1 (es) 1984-11-26 1985-11-01 Fordonal Sa Procedimiento de preparacion de un derivado de piracina.
JPS63139949A (ja) 1986-12-02 1988-06-11 Fuji Photo Film Co Ltd 新規ピラゾロン染料
SE8704248D0 (sv) 1987-10-30 1987-10-30 Haessle Ab Medical use
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
ATE431347T1 (de) 1996-10-14 2009-05-15 Bayer Healthcare Ag Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE10021069A1 (de) 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
AU2002221827A1 (en) 2000-11-22 2002-06-03 Bayer Aktiengesellschaft Novel lactame-substituted pyrazolopyridine derivatives
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
JP4765623B2 (ja) 2003-05-09 2011-09-07 旭硝子株式会社 ２−クロロ−５−フルオロ−３−置換ピリジンまたはその塩の製造方法
CN100355732C (zh) 2003-11-03 2007-12-19 上海药明康德新药开发有限公司 2－氯－5－氟－烟酸酯及酸的制备方法
US7528132B2 (en) 2005-01-26 2009-05-05 Schering Corporation Kinase inhibitors
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
CA2743864A1 (en) * 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
CA2803688A1 (en) 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
JP5940062B2 (ja) 2010-07-09 2016-06-29 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 環縮合４−アミノピリミジンおよび可溶性グアニル酸シクラーゼの刺激剤としてのその使用
RU2606641C2 (ru) 2010-08-31 2017-01-10 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010040234A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
WO2012143510A1 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
EP2716642B1 (en) 2011-05-30 2016-07-20 Astellas Pharma Inc. Imidazopyridine compound
CN103906752B (zh) 2011-07-06 2016-08-24 拜耳知识产权有限责任公司 杂芳基取代的吡唑并吡啶及其用作可溶性鸟苷酸环化酶刺激剂的用途
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
BR112014005110A2 (pt) 2011-09-02 2017-04-18 Bayer Ip Gmbh pirimidinas aneladas substituídas e utilização das mesmas
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200352A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200349A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
JP6140738B2 (ja) 2012-03-06 2017-05-31 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アザ二環およびその使用
HK1220974A1 (zh) 2013-03-01 2017-05-19 Bayer Pharma Aktiengesellschaft 三氟甲基取代的稠合嘧啶类及其用途
WO2014131741A1 (de) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Benzyl-substituierte pyrazolopyridine und ihre verwendung
WO2015018808A1 (de) 2013-08-08 2015-02-12 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyrazincarboxamide und ihre verwendung

Also Published As

Publication number Publication date
AU2014289312A1 (en) 2016-02-11
DOP2016000006A (es) 2016-02-15
JP2016523944A (ja) 2016-08-12
EP3019506A1 (de) 2016-05-18
CA2917682A1 (en) 2015-01-15
GT201600002A (es) 2018-12-19
KR20160030541A (ko) 2016-03-18
US9605008B2 (en) 2017-03-28
PH12016500065A1 (en) 2016-07-04
PE20160201A1 (es) 2016-05-06
TN2016000006A1 (en) 2017-07-05
AP2016008970A0 (en) 2016-01-31
IL243525A0 (en) 2016-02-29
US20160145271A1 (en) 2016-05-26
WO2015004105A1 (de) 2015-01-15
TW201542569A (zh) 2015-11-16
EA201600096A1 (ru) 2016-10-31
CU20160004A7 (es) 2016-06-29
CN105745215A (zh) 2016-07-06
MX2016000258A (es) 2016-04-28
SG11201600038UA (en) 2016-02-26
UY35652A (es) 2015-01-30

Similar Documents

Publication Publication Date Title
CL2015000120A1 (es) Compuestos derivados de acidos 5-aminotetrahidroquinolin-2-carboxilicos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de hipertension pulmonar, insuficiencia cardiaca, angina de pecho, hipertension, enfermedades tromboembolicas, enfermedades fibroticas, isquemias, entre otras.
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
WO2015027206A8 (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
CL2014001389A1 (es) Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing.
CL2014001779A1 (es) Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
DK3558990T3 (da) Tetrahydroimidazo[4,5-c]pyridinderivater som pd-l1 internaliseringsinducere
CL2015001163A1 (es) Compuestos derivados de imidazo[1,2-a]piridincarboxamidas aminosustituidas; procedimiento para prepararlos; medicamento; procedimiento para el tratamiento y/o la prevencion; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina de pecho, hipertension e hipertension pulmonar, entre otras enfermedades.
WO2015061572A8 (en) Inhibitors of the fibroblast growth factor receptor
LT3805220T (lt) Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CL2014000504A1 (es) Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
IL311677B2 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX384244B (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
EA201691194A1 (ru) Стимуляторы ргц
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
DK3658140T3 (da) Kombinationer af aprocitentan med yderligere aktive bestanddele til behandlingen af resistent hypertension
LT3197892T (lt) Naftiridino dariniai, kaip alfa v beta 6 integrino antagonistai, skirti fibrozinių ligų gydymui
UY34305A (es) Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
EA201600128A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2(1Н)-ОНА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ И АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ
MX2018016299A (es) Derivados de imidazo[1,2-a]piridina, métodos para preparar los mismos y uso de los mismos.
HUE051448T2 (hu) Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
WO2015171526A3 (en) Tricyclic pyrazolopyridine compounds